ArticleOncogene2017
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- VersatileProceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025Review
- Assessing cancer therapeutic efficacy in vivo using [Science advances · 2025Article
- Precise Readout of MEK1 Proteoforms upon MAPK Pathway Modulation by Individual Ion Mass Spectrometry.Analytical chemistry · 2024Article
- BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Nature reviews. Clinical oncology · 2024Review
- Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.BMC medical genomics · 2023Article
- Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.Cancers · 2022Review
- BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases.Neoplasia (New York, N.Y.) · 2020Article
- Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.Oncogene · 2020Article
- Translation regulation in skin cancer from a tRNA point of view.Epigenomics · 2019Review
- A model for RAS mutation patterns in cancers: finding the sweet spot.Nature reviews. Cancer · 2018Review
- Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches.Current oncology reports · 2018Review
- miR‑367 enhances the proliferation and invasion of cutaneous malignant melanoma by regulating phosphatase and tensin homolog expression.Molecular medicine reports · 2018Article
- Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.BMC cancer · 2018Article
- CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma.Frontiers in oncology · 2018Review
- Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.